Compare Boston Scientific Corporation (BSX) vs MPLX LP (MPLX) Price & Performance

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

MPLX trades at $59.76, up 1.81% with a bullish technical outlook. The stock shows strong profitability with a 40.45% net income margin and a P/E of 12.75. Recent Q2 2026 earnings missed expectations, but revenue grew to $11.7B in 2026. The company announced a $2.25 billion senior notes offering on August 10, 2026, to fund growth projects, supporting its fee-based infrastructure model.

Outlook is positive with a consensus price target of $61.50, though risks include rising capital spending and leverage. The dividend yield remains attractive, with a $1.08 distribution declared for H2-2026. Investors should weigh solid cash flow against execution risks in expansion initiatives.